Pralmorelin: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Pralmorelin}} | |||
== | == Overview == | ||
[[File:Pralmorelin.svg|thumb|right|Chemical structure of Pralmorelin]] | |||
'''Pralmorelin''' is a synthetic peptide that acts as a [[growth hormone secretagogue]]. It is primarily used in clinical settings to assess the function of the [[pituitary gland]] and the [[hypothalamus]]. Pralmorelin stimulates the release of [[growth hormone]] (GH) by mimicking the action of the natural hormone [[ghrelin]]. | |||
== | == Mechanism of Action == | ||
Pralmorelin | Pralmorelin binds to the [[growth hormone secretagogue receptor]] (GHS-R) located in the pituitary gland and hypothalamus. This binding triggers a cascade of intracellular events that lead to the secretion of growth hormone. The action of Pralmorelin is similar to that of ghrelin, which is an endogenous ligand for the GHS-R. | ||
== | == Clinical Use == | ||
Pralmorelin is used in diagnostic tests to evaluate growth hormone deficiency and other disorders related to the [[endocrine system]]. It is administered intravenously, and the subsequent levels of growth hormone in the blood are measured to assess the responsiveness of the pituitary gland. | |||
== | == Pharmacokinetics == | ||
Pralmorelin is rapidly absorbed and has a short half-life, which makes it suitable for use in diagnostic testing. Its effects are transient, and it is quickly cleared from the body. | |||
== Side Effects == | |||
The administration of Pralmorelin is generally well-tolerated. However, some patients may experience mild side effects such as headache, nausea, or dizziness. These effects are usually temporary and resolve without intervention. | |||
== Research and Development == | |||
Pralmorelin has been studied for its potential use in treating conditions such as [[cachexia]] and [[muscle wasting]] due to its ability to stimulate growth hormone release. However, its primary use remains in diagnostic testing. | |||
== Related Pages == | |||
* [[Growth hormone]] | |||
* [[Ghrelin]] | * [[Ghrelin]] | ||
* [[ | * [[Pituitary gland]] | ||
* [[ | * [[Endocrine system]] | ||
[[Category:Peptides]] | [[Category:Peptides]] | ||
[[Category: | [[Category:Endocrinology]] | ||
Latest revision as of 03:47, 13 February 2025
Overview[edit]
Pralmorelin is a synthetic peptide that acts as a growth hormone secretagogue. It is primarily used in clinical settings to assess the function of the pituitary gland and the hypothalamus. Pralmorelin stimulates the release of growth hormone (GH) by mimicking the action of the natural hormone ghrelin.
Mechanism of Action[edit]
Pralmorelin binds to the growth hormone secretagogue receptor (GHS-R) located in the pituitary gland and hypothalamus. This binding triggers a cascade of intracellular events that lead to the secretion of growth hormone. The action of Pralmorelin is similar to that of ghrelin, which is an endogenous ligand for the GHS-R.
Clinical Use[edit]
Pralmorelin is used in diagnostic tests to evaluate growth hormone deficiency and other disorders related to the endocrine system. It is administered intravenously, and the subsequent levels of growth hormone in the blood are measured to assess the responsiveness of the pituitary gland.
Pharmacokinetics[edit]
Pralmorelin is rapidly absorbed and has a short half-life, which makes it suitable for use in diagnostic testing. Its effects are transient, and it is quickly cleared from the body.
Side Effects[edit]
The administration of Pralmorelin is generally well-tolerated. However, some patients may experience mild side effects such as headache, nausea, or dizziness. These effects are usually temporary and resolve without intervention.
Research and Development[edit]
Pralmorelin has been studied for its potential use in treating conditions such as cachexia and muscle wasting due to its ability to stimulate growth hormone release. However, its primary use remains in diagnostic testing.
